Fast Simple Method to Make and Modify Aids Medicine
CCNY's HIV researchers Hari Akula [left] and Mahesh Lakshman.
As the HIV/AIDS epidemic approaches its fourth decade, each year brings promising news of pioneering research to alleviate the scourge. Add City College of New York scientists to the list with a rapid method to access new molecules that could inhibit the virus that causes AIDS.
The CCNY research led by Mahesh K. Lakshman, vice chair of the Department of Chemistry and Biochemistry and Ph.D. student Hari Akula, focuses on the modification of nucleosides. These are genetic building materials in all living organisms and because of this they possess great potential as antiviral agents.
The ability to rapidly modify the structures of natural nucleosides is at the core of developing potential pharmaceutical agents. This is likely to yield diverse compounds that can then be tested to gain insight into structural effects on biological activity. “Such is the case with modifying pyrimidine nucleosides, including AZT (zidovudine), a drug used in the control of HIV infections,” said Lakshman, a Fellow of the Royal Society of Chemistry.
In this context, Lakshman and Akula have developed a simple and fast method for preparing new pyrimidine nucleoside analogues, a family in which AZT belongs, and for modifying AZT itself. Along with their collaborators at the Rega Institute for Medical Research, they have identified several new compounds that are active against the more virulent HIV-1 and the less common and less pathogenic HIV-2.
Their research appears in the Royal Society of Chemistry publication “Organic and Biomolecular Chemistry.”
According to the Geneva-based UNAIDS, as of 2015, an estimated 35 million people have died globally from AIDS-related illnesses since the start of the epidemic.
HIV, however, is no longer considered a death sentence following the development of antiretroviral therapy. As a result, UNAIDS estimates that more than 18 million people around the world are living with HIV.
Akula, H.K., Kokatla, H., Andrei, G., Snoeck, R., Schols, D., Balzarini, J., Yang, L. and Lakshman, M.K., 2017. Facile functionalization at the C4 position of pyrimidine nucleosides via amide group activation with (benzotriazol-1-yloxy) tris (dimethylamino) phosphonium hexafluorophosphate (BOP) and biological evaluations of the products. Organic & Biomolecular Chemistry.
This article has been republished from materials provided by The City College of New York. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018